{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:15:59Z","timestamp":1790363759318,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/j.curtheres.2003.11.003","type":"journal-article","created":{"date-parts":[[2004,1,2]],"date-time":"2004-01-02T10:29:21Z","timestamp":1073039361000},"page":"646-661","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review"],"prefix":"10.1016","volume":"64","author":[{"given":"Peter","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2003.11.003_BIB1","series-title":"The Quinolones","first-page":"1","article-title":"The quinolones: History and overview","author":"Ball","year":"2000"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/13543784.7.5.761","article-title":"Therapeutic advances of new fluoroquinolones","volume":"7","author":"Ball","year":"1998","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jac\/45.5.557","article-title":"Quinolone-induced QT interval prolongation: A not-so-unexpected class effect","volume":"45","author":"Ball","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB4","series-title":"Quinolone Antimicrobial Agents","article-title":"Treatment of community-acquired respiratory tract infections","author":"Ball","year":"2003"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/srin.2001.25628","article-title":"Future of the quinolones","volume":"16","author":"Ball","year":"2001","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1473-3099(02)00316-X","article-title":"Treatment of drug-resistant pneumococcal pneumonia","volume":"2","author":"Garau","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteraemia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB10","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niedermann","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 4","key":"10.1016\/j.curtheres.2003.11.003_BIB11","first-page":"S1","article-title":"Guidelines for the management of community-acquired pneumonia in adults","volume":"56","author":"British Thoracic Society","year":"2001","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2003.11.003_BIB12","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0924-8579(01)00402-2","article-title":"Japanese guidelines for the management of community-acquired pneumonia","volume":"18","author":"Yanagihara","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl A","key":"10.1016\/j.curtheres.2003.11.003_BIB13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jac\/40.suppl_1.59","article-title":"The role of fluoroquinolones in respiratory tract infections","volume":"40","author":"Grossman","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00001432-199912000-00003","article-title":"The role of fluoroquinolones in chronic obstructive pulmonary disease","volume":"12","author":"Banerjee","year":"1999","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB15","first-page":"186","article-title":"Causes, epidemiology and treatment of bronchial infections","volume":"17","author":"Ball","year":"2000","journal-title":"Infect Med"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/48.5.659","article-title":"Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000","volume":"48","author":"Ho","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0924-8579(02)00125-5","article-title":"Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999\u20132000","volume":"20","author":"Critchley","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1086\/322658","article-title":"A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae","volume":"33","author":"Weiss","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1086\/319222","article-title":"Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case control study","volume":"32","author":"Ho","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2003.11.003_BIB21","doi-asserted-by":"crossref","first-page":"S005","DOI":"10.1016\/S1201-9712(03)90065-8","article-title":"Why do we need to eradicate pathogens in respiratory tract infections?","volume":"7","author":"Garau","year":"2003","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jac\/dkf152","article-title":"Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance","volume":"50","author":"Boswell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkf095","article-title":"Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae","volume":"50","author":"Madaras-Kelly","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jac\/dkf177","article-title":"AUC\/MIC relationships to different endpoints of the antimicrobial effect: Multiple-dose in vitro simulations with moxifloxacin and levofloxacin","volume":"50","author":"Firsov","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.curtheres.2003.11.003_BIB25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/43.suppl_1.55","article-title":"Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy","volume":"43","author":"Highet","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1128\/AAC.42.5.1098","article-title":"Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection","volume":"42","author":"Preston","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2003.11.003_BIB28","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1086\/319375","article-title":"What have we learned from pharmacokinetic and pharmacodynamic theories?","volume":"32","author":"Schentag","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/40.4.573","article-title":"Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy","volume":"40","author":"Andrews","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB31","series-title":"Tavanic (levofloxacin) prescribing information","year":"2003"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomised study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00365549850160710","article-title":"A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia","volume":"30","author":"Norrby","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0149-2918(01)80047-3","article-title":"Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: Integrated results from four open-label, multicenter, phase III clinical trials","volume":"23","author":"Fogarty","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-0691.1999.tb00705.x","article-title":"Comparative study of levofloxacin and amoxicillin-clavulanic acid in adults with mild-to-moderate community-acquired pneumonia","volume":"5","author":"Carbon","year":"1999","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl S1","key":"10.1016\/j.curtheres.2003.11.003_BIB36","first-page":"46","article-title":"Levofloxacin therapy for community acquired pneumonia due to atypical and intracellular micro-organisms","volume":"47","author":"O'Hare","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl S1","key":"10.1016\/j.curtheres.2003.11.003_BIB37","first-page":"45","article-title":"Levofloxacin is safe and effective in the management of community acquired pneumonia due to Legionella","volume":"47","author":"Yu","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treatment of community-acquired pneumonia","volume":"283","author":"Marrie","year":"2000","journal-title":"JAMA"},{"issue":"Suppl S1","key":"10.1016\/j.curtheres.2003.11.003_BIB39","first-page":"44","article-title":"Effect of new guidelines and a respiratory quinolone on clinical outcomes in hospitalized patients with communityacquired pneumonia","volume":"47","author":"Marras","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jac\/43.4.529","article-title":"Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study","volume":"43","author":"Shah","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00019048-199802000-00009","article-title":"Multicenter randomised study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis","volume":"7","author":"Habib","year":"1998","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jac\/44.4.501","article-title":"Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis","volume":"44","author":"Wilson","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/rmed.1999.0708","article-title":"Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis","volume":"94","author":"Chodosh","year":"2000","journal-title":"Respir Med"},{"issue":"Suppl 11","key":"10.1016\/j.curtheres.2003.11.003_BIB44","first-page":"S30","article-title":"Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results","volume":"20","author":"Ramirez","year":"1999","journal-title":"J Respir Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0924-8579(01)00435-6","article-title":"Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis","volume":"18","author":"Masterton","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 6A","key":"10.1016\/j.curtheres.2003.11.003_BIB46","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1016\/0002-9343(91)90317-Q","article-title":"Treatment of acute exacerbations of chronic bronchitis: State of the art","volume":"91","author":"Chodosh","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/517802","article-title":"The infection-free interval: Its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis","volume":"28","author":"Anzueto","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB48","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/ajhp\/59.14.1357","article-title":"Cost-effectiveness of gemifloxacin: Results from the GLOBE study","volume":"59","author":"Halpern","year":"2002","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl S1","key":"10.1016\/j.curtheres.2003.11.003_BIB49","first-page":"43","article-title":"Greater improvement in health status of smokers and ex-smokers treated for AECB with gemifloxacin versus clarithromycin: The Globe Study","volume":"47","author":"Jones","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 25","key":"10.1016\/j.curtheres.2003.11.003_BIB50","first-page":"148S","article-title":"Changes in health status following an acute exacerbation of chronic bronchitis","volume":"10","author":"Anie","year":"1997","journal-title":"Eur Respir J"},{"issue":"Suppl 30","key":"10.1016\/j.curtheres.2003.11.003_BIB51","first-page":"19S","article-title":"Annual rate of health status decline in COPD patients is significantly related to frequency of acute exacerbations","volume":"14","author":"Spencer","year":"1999","journal-title":"Eur Respir J"},{"issue":"Suppl A","key":"10.1016\/j.curtheres.2003.11.003_BIB52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/43.suppl_1.107","article-title":"Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis","volume":"43","author":"Destache","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB53","series-title":"Cipro (ciprofloxacin)","year":"2003"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB54","series-title":"Avelox (moxifloxacin) [online]","year":"2003"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199921050-00005","article-title":"Comparative tolerability of the newer fluoroquinolone antibacterials","volume":"21","author":"Ball","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/515104","article-title":"Fluoroquinolone toxicity profiles: A review focusing on newer agents","volume":"28","author":"Lipsky","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002018-199513060-00004","article-title":"Tolerability of fluoroquinolone antibiotics. Past, present and future","volume":"13","author":"Ball","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00003495-199447040-00008","article-title":"Levofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy [published correction appears in Drugs. 1994;48:132]","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB59","series-title":"Poster presented at the 42nd Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Over 10 million patient uses: An update on the safety profile of oral moxifloxacin","author":"Iannini","year":"2002"},{"issue":"Suppl 11","key":"10.1016\/j.curtheres.2003.11.003_BIB60","first-page":"S70","article-title":"Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxyquinolone","volume":"20","author":"Breen","year":"1999","journal-title":"J Respir Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the quinolone antibacterials [published correction appears in J Antimicrob Chemother 1994; 34:851]","volume":"33","author":"Domagala","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB62","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1751-1097.1995.tb02392.x","article-title":"Fluoroquinolone photosensitization: A review of clinical and laboratory studies","volume":"62","author":"Ferguson","year":"1995","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB63","first-page":"404","article-title":"Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice","volume":"43","author":"Wagai","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10715769209083143","article-title":"Possible reasons for differences in phototoxic potential of 5 quinolone antibacterial agents: Generation of toxic oxygen","volume":"17","author":"Wagai","year":"1992","journal-title":"Free Radic Res Commun"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB65","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1128\/AAC.37.10.2217","article-title":"Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light","volume":"37","author":"Marutani","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0735-1097(95)00426-2","article-title":"Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events","volume":"27","author":"Molnar","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB68","series-title":"Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products","author":"Committee for Proprietary Medicinal Products","year":"1997"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200225040-00004","article-title":"Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview","volume":"25","author":"De Ponti","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB70","first-page":"528","article-title":"QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin","volume":"107","author":"Samaha","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1592\/phco.21.3.361.34204","article-title":"Gatifloxacin-induced QTc prolongation and ventricular tachycardia","volume":"21","author":"Iannini","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB72","first-page":"46","article-title":"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones","volume":"322","author":"Iannini","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB73","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin","volume":"21","author":"Frothingham","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1086\/342564","article-title":"Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia","volume":"35","author":"Frothingham","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB75","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1592\/phco.22.8.663.33201","article-title":"Torsade de pointes associated with fluoroquinolones","volume":"22","author":"Owens","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB76","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1086\/339075","article-title":"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors","volume":"34","author":"Bertino","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB77","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jac\/46.5.847","article-title":"Quinolone-induced QT interval prolongation: A not-so-unexpected class effect","volume":"46","author":"Kahn","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB78","first-page":"419","article-title":"Fluoroquinolone safety profiles\u2014a review","volume":"20","author":"Tillotson","year":"2002","journal-title":"Todays Ther Trends"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.44.2.261-266.2000","article-title":"Ultrastructure of Achilles tendon of rats treated with ofloxacin and fed a normal or magnesium-deficient diet","volume":"44","author":"Shakibaei","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB80","first-page":"75","article-title":"Features of tendon disorders with fluoroquinolones","volume":"49","author":"Royer","year":"1994","journal-title":"Therapie"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1529-0131(200106)45:3<235::AID-ART254>3.0.CO;2-7","article-title":"Tendon disorders attributed to fluoroquinolones: A study of 42 spontaneous reports in the period 1988 to 1998","volume":"45","author":"van der Linden","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s150100070050","article-title":"Fluoroquinolone-induced tendinopathy: Also occurring with levofloxacin","volume":"28","author":"Fleisch","year":"2000","journal-title":"Infection"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB83","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00007611-200093050-00008","article-title":"Quinolones and tendon ruptures","volume":"93","author":"Casparian","year":"2000","journal-title":"South Med J"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2125.1999.00016.x","article-title":"Achilles tendonitis associated with fluoroquinolones","volume":"48","author":"van der Linden","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB85","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bmj.324.7349.1306","article-title":"Fluoroquinolones and risk of Achilles tendon disorders: Case control study","volume":"324","author":"van der Linden","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB86","first-page":"419","article-title":"Tendon disorders with fluoroquinolones","volume":"51","author":"Pierfitte","year":"1996","journal-title":"Therapie"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB87","series-title":"Tavanic\u2014Important Pharmacovigilance Information Concerning Tavanic (Levofloxacin) [in French]","author":"Rothschild","year":"2001"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB88","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/00007611-199109000-00027","article-title":"Ofloxacin-induced severe hepatitis","volume":"84","author":"Blum","year":"1991","journal-title":"South Med J"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB89","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1592\/phco.22.9.794.34066","article-title":"Antimicrobial-associated acute hepatitis","volume":"22","author":"Nicholson","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB90","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1086\/338156","article-title":"Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease","volume":"33","author":"Karim","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM200002033420517","article-title":"Acute eosinophilic hepatitis from trovafloxacin","volume":"342","author":"Chen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB92","first-page":"15","article-title":"Review: Wherefore withdrawal? The science behind recent drug withdrawals and warnings","volume":"4","author":"Suchard","year":"2001","journal-title":"Int J Med Toxicol"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB93","series-title":"Public Statement on Trovan\/Trovan IV\/Turvel\/Turvel IV (Trovafloxacin\/Alatrofloxacin). Recommendation to Suspend the Marketing Authorisation in the European Union","author":"European Agency for the Evaluation of Medicinal Products","year":"1999"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB94","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","article-title":"Temafloxacin syndrome: A review of 95 cases","volume":"18","author":"Blum","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB95","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1592\/phco.21.20.1579.34479","article-title":"Gatifloxacin-associated acute hepatitis","volume":"21","author":"Henann","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"Suppl 3","key":"10.1016\/j.curtheres.2003.11.003_BIB96","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000057843","article-title":"Latest industry information on the safety profile of levofloxacin in Japan","volume":"47","author":"Yagawa","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.curtheres.2003.11.003_BIB97","series-title":"Recent Advances in Chemotherapy: Proceedings of the 18th International Congress of Chemotherapy","first-page":"349","article-title":"Ciprofloxacin safety relative to temafloxacin and lomefloxacin","author":"Echols","year":"1994"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X03002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X03002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T16:31:36Z","timestamp":1585413096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X03002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0011393X03002017"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2003.11.003","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}